Cicero Giuseppe, De Luca Rossella, Blasi Livio, Pepe Alessio, Pavone Carlo, Simonato Alchiede, Dieli Francesco
aDepartment of Surgical, Oncological and Oral Sciences, Section of Medical Oncology bDepartment of Surgical, Oncological and Oral Sciences, Section of Urology cCentral Laboratory of Advances Diagnosis and Biomedical Research, University of Palermo dMedical Oncology Unit, ARNAS Hospidaly Civico, Di Cristina, Benfratelli, Palermo, Italy.
Anticancer Drugs. 2017 Oct;28(9):1047-1052. doi: 10.1097/CAD.0000000000000549.
The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA response and reduction in pain of 0.57 (95% confidence interval: -0.30 to 0.80) (P=0.005). Meanwhile, regression analysis revealed that PSA levels are predictive of OS. There was a positive correlation with OS, which showed a value of R to 0.50 with a slope of 1.44 (P=0.0021). Abiraterone is a well-tolerated and effective treatment modality for patients affected with metastatic castration-resistant prostate cancer. The drug has a better tolerability profile, gives significant pain relief, and increases the survival rate.
本研究的目的是评估阿比特龙对多西他赛治疗后病情进展的意大利转移性前列腺癌患者的疗效。我们对60例患者进行了回顾性分析。血清前列腺特异性抗原（PSA）降低是评估阿比特龙联合泼尼松治疗疗效的主要终点，而疼痛减轻、安全性、无进展生存期、缓解率和总生存期（OS）则是次要终点。观察到PSA反应与OS之间存在显著相关性。此外，布拉维-皮尔逊指数（r）相关性使我们能够观察到PSA反应与疼痛减轻之间存在显著的负相关，相关性为0.57（95%置信区间：-0.30至0.80）（P=0.005）。同时，回归分析显示PSA水平可预测OS。与OS呈正相关，R值为0.50，斜率为1.44（P=0.0021）。阿比特龙是治疗转移性去势抵抗性前列腺癌患者耐受性良好且有效的治疗方式。该药物耐受性更好，能显著缓解疼痛，并提高生存率。
